1. Introduction {#sec1}
===============

Hepatocellular carcinoma (HCC), constituting 90% of all primary liver tumors, is the fifth most malignant tumor worldwide. A total of 841,000 newly diagnosed cases and over 782,000 related deaths have been reported \[[@B1]\]. Due to its epidemiological features, HCC has received a lot of research attention. Although the surgical techniques, diagnostic methods, and combined treatments have greatly improved, patients diagnosed with HCC have a poor long-term prognosis, largely due to the high rates of intrahepatic metastasis (44.0--62.2%) and a 5-year survival rate of just 3% after surgical removal \[[@B2]--[@B4]\]. HCC is often diagnosed at advanced stages after the appearance of symptoms. A better understanding of the molecular mechanisms of hepatocarcinogenesis will therefore contribute to the development of a molecular target therapy for this type of cancer. Novel molecular biomarkers that can precisely evaluate disease progression and clinical results in the early stages of disease are urgently needed to facilitate an early diagnosis and for the development of personalized treatment.

ATAD2, an evolutionarily conserved AAA protein mapped to chromosome 8q24, possesses two AAA+ domains and a bromodomain (BRD) \[[@B5]\]. The unique structure of ATAD2 suggests that it plays an important role in regulating ATPase activity, protein multimerization, and binding to acetylated histones or nonhistones \[[@B6]\]. ATAD2 is often overexpressed in many human tumors, and its aberrant expression has been correlated with high histologic grades, poor overall survival (OS), tumor metastasis, and recurrence \[[@B7]--[@B10]\]. ATAD2 has also been identified as a coactivator of hormone-induced nuclear receptors (oestrogen receptor alpha (ER*α*) and androgen receptor (AR)), E2Fs, and c-myc for the promotion of tumor progression \[[@B5], [@B11], [@B12]\]. Previous studies have suggested that silencing ATAD2 may inhibit malignant tumor biological phenotypes, such as invasion, metastasis, and proliferation, consistent with our previous results regarding HCC \[[@B13]\]. These findings clearly indicate that the status of ATAD2 expression plays a vital role in the occurrence and prognosis of tumors, particularly HCC. Nonetheless, a comprehensive bioinformatics analysis of the functions of ATAD2 has not yet been performed. Thus, in the present study, we performed an integrated analysis of our institutional data and datasets from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Oncomine to determine the diagnostic value and functions of ATAD2 in HCC.

2. Materials and Methods {#sec2}
========================

2.1. Patients Tissue Specimens {#sec2.1}
------------------------------

Tumor specimens (*n* = 80) and adjacent noncancerous tissues (*n* = 20) were obtained from patients with HCC who had only undergone surgical resection with curative intent at the First Affiliated Hospital of China Medical University from July 2012 to December 2014 (China Medical University date, CMUD). The pathological diagnoses and differentiations were confirmed by three independent pathologists according to the current classification system for HCC (World Health Organization). The clinicopathological features of all patients are provided in [Table 1](#tab1){ref-type="table"}. Fresh specimens were snap-frozen in liquid nitrogen or stored at −80°C immediately after resection. This study was approved by the Institutional Ethics Committee of China Medical University. Written informed consent was obtained from all patients.

2.2. Immunohistochemistry and Assessment of Immunostaining {#sec2.2}
----------------------------------------------------------

Immunohistochemistry was conducted as previously described \[[@B13]\]. ATAD2 expression in protein levels was scored semiquantitatively also according to the previous contents described \[[@B13], [@B14]\]. Briefly, samples were considered positive if the nucleus or cytoplasm of the sample cells presented a positive staining. The percent positivity and staining intensity were, respectively, defined as different scores. The scores of the percent positivity and the staining intensity were combined and assessed. Finally, the immunohistochemical ATAD2 staining was grouped into two categories: low expression and high expression.

2.3. TCGA Dataset {#sec2.3}
-----------------

The mRNA expression datasets of the genes from the Cancer Genome Atlas datasets liver HCC (TCGA LIHC), containing 374 HCC samples and 50 normal samples, were downloaded for further analysis (<http://cancergenome.nih.gov/>). The clinical datasets from 374 patients with HCC, including age, gender, race, cirrhosis, histological type, family cancer history, grade, vascular tumor cell type, TNM stage, and pathological T/N/M stage, were also estimated. The data were used to assess the correlation between the ATAD2 mRNA expression levels and prognosis.

2.4. Oncomine and GEO Datasets {#sec2.4}
------------------------------

Other open online datasets, such as Oncomine (<http://www.oncomine.org>) and the Gene Expression Omnibus (GEO) (<https://www.ncbi.nlm.nih.gov/geo/>), were also checked for any HCC-relevant RNA-seq levels to analyze by combining the search terms "HCC", "hepatocellular", "liver", "cancer", "tumor", and "malignant" using "or" or "and". Further details on the microarray data and platforms are provided in [Table 1](#tab1){ref-type="table"}.

2.5. Bioinformatics Analysis {#sec2.5}
----------------------------

The RNA-seq data downloaded from TCGA and GEO were analyzed using the edgeR package of R language (version 3.5.1) to identify the differentially expressed genes (DEGs) between HCC tissues and nontumor tissues. We defined *P* − adj \< 0.05 and (∣log2*FC*∣) \> 1 as the thresholds for screening the DEGs. The R package of "WGCNA" (Langfelder & Horvath, 2008) was used to construct a coexpression network for these DEGs in 374 HCC samples using the corresponding clinical information. We identified biologically significant modules using Pearson\'s correlation test to evaluate the association between modules and clinical features, including ATAD2 expression status. The module that showed the highest correlation with aberrant ATAD2 expression was selected. The Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.8 (<https://david.ncifcrf.gov/>) was used to categorize the gene data for the ATAD2-related target modules, namely, biological process, cellular component, and molecular function, using the FAT datasets of the Gene Ontology (GO) functional and pathway enrichment analysis using Kyoto Encyclopedia of Genes and Genomes (KEGG) and visualized using GraphPad Prism 7 (San Diego, CA, USA). Then, the gene significance (GS), high module membership (MM), and MCODE score for different genes in the gene modules of interest were calculated using the GS value, the *R* value from the MM correlation analysis, and the degree numbers from MCODE score analysis by ranking the top 30 genes. Based on the overlapping genes between the GS, MM, and MCODE scores, the hub genes were identified.

2.6. Liver Cancer Cell Line Cell Cultures and Construction of RNAi Lentivirus Vector {#sec2.6}
------------------------------------------------------------------------------------

The liver cancer cell lines HepG2 and Bel-7402 were obtained from the Shanghai Cell Bank (Shanghai, China). HepG2 and Bel-7402 were grown in DMEM (Gibco, USA). All media were supplemented with 10% fetal bovine serum (FBS = (Invitrogen) and 100 U/ml penicillin (Sigma, St. Louis, MO). The RNAi lentivirus vector for the downregulation of ATAD2 expression was constructed and transfected into the HepG2 and Bel-7402 cells, as previously reported \[[@B14]\].

2.7. Cell Cycle Analysis {#sec2.7}
------------------------

The HepG2 and Bel-7402 cells were placed in 6-well plates and transfected with ATAD2-RNAi-lentivirus or control. The cells were seeded at a density of 5 × 10^5^ per well and trypsinized. Cell cycle analysis was performed after staining with propidium iodide (Keygene, China). The cell cycle distribution was quantified using a flow cytometer.

2.8. Western Blotting {#sec2.8}
---------------------

The cells were lysed with RIPA buffer (Beyotime, China) and centrifuged at 12,000 g for 30 min at 4°C. The protein concentration was determined using the Bradford method in a SpectraMax M5 multidetection reader (MDS, USA) at 562 nm. Equal amounts of protein (10 *μ*g) were run on 10% to 12% SDS-PAGE acrylamide gels and transferred to PVDF membranes (Millipore, Billerica, MA, USA). After the blocking of nonspecific binding sites for 2 h with 5% nonfat milk in TBST, the membrane was incubated overnight at 4°C with primary antibodies, including anti-ATAD2 (Abcam, UK), anticyclin D1, anticyclin C (Proteintech, USA) (both diluted at 1 : 1,000). The membranes were then incubated with secondary antibodies for 1 h at room temperature. GAPDH was used as the loading control for the human samples. The immunoblots were visualized using an ECL system (Millipore, Bedford, MA, USA).

2.9. Statistical Analysis {#sec2.9}
-------------------------

SPSS 23.0 (SPSS Inc., Chicago, IL, USA) software for Windows was used for the statistical analysis. The association between ATAD2 expression and the clinicopathological features of the HCC patients were evaluated using the Chi-squared (*χ*^2^) test. The data for ATAD2 expression were presented as the mean ± standard deviation (SD) in our Center for each of the datasets. The independent-samples *T* test was used to compare the differential ATAD2 expression levels in the different patients (HCC vs. normal) and the clinicopathological features. In order to assess the overall diagnostic value of ATAD2 from 28 databases to distinguish the HCC patients from the controls, the pooled sensitivity, specificity, diagnostic odds ratio (DOR), the summary receiver operator characteristic (SROC) curve, and the area under the curve (AUC) were calculated using STATA 12.0. The sensitivity and specificity of each biomarker (ATAD2, GPC3, and AFP) for the diagnosis of HCC and the AUC value with 95% CI were calculated using GraphPad Prism 5 (San Diego, CA, USA). The coincidence rate was determined as follows: (true positive + true negative)/(true positive + true negative + false positive + false negative). The differential expression levels of ATAD2, the ROC curves, and the cell cycle results were also visualized using GraphPad Prism 5. The Kaplan-Meier method was used to calculate the patients\' survival using the log-rank test. A Cox repression model was performed for the univariate and multivariate analysis of the prognostic variables. All *P* values were two-sided, and *P* \< 0.05 was considered statistically significant. A comprehensive perspective on ATAD2 expression was analyzed by integrating open online data in the form of meta-analysis using STATA 12.0 (StataCorp, College Station, TX, USA). The total SMD (Standard Mean Difference) was computed. When SMD \> 0 and its 95% CI did not cross, an integer of 0 indicated that ATAD2 was significantly overexpressed in tumors compared to nontumor tissues. The comprehensive efficiency of ATAD2 in distinguishing tumor from nontumor tissues was determined using SROC curves. The overall design of the present study is shown in Figure [S1](#supplementary-material-1){ref-type="supplementary-material"} in the form of a flow chart.

3. Results {#sec3}
==========

3.1. ATAD2 Expression and Its Relationships with Clinicopathological Features in HCC Based on the CMUD and TCGA LIHC Datasets {#sec3.1}
-----------------------------------------------------------------------------------------------------------------------------

We first explored the expression of ATAD2 mRNA in 33 types of tumors based on gene expression profiling interactive analysis (GEPIA). As shown in Figure [S2A](#supplementary-material-1){ref-type="supplementary-material"}, ATAD2 expression was increased in 17 HCC tumors. To further detect the expression of ATAD2 in HCC, the CMUD and TCGA LIHC datasets were analyzed. The CMUD results suggested that ATAD2 was overexpressed in a larger percentage (65%, 52/80) of HCC samples compared to nontumor liver specimens by *in situ* hybridization (ISH) (30%, 6/20, Figure [S3](#supplementary-material-1){ref-type="supplementary-material"}). The high levels of ATAD2 protein were correlated with tumor size (*P* = 0.018), metastasis (*P* = 0.009), serum alpha-fetoprotein (AFP) (*P* = 0.010), and TNM stage (*P* = 0.033, [Table 2](#tab2){ref-type="table"}). We also found that the specimens with metastasis and a high TNM stage accumulated ATAD2 protein in the cytoplasm and/or nucleus (Figures [1(a)](#fig1){ref-type="fig"}--[1(d)](#fig1){ref-type="fig"}) by immunohistochemistry (IHC). In the TCGA data, which contained RNA-seq and clinical datasets from 374 HCC patients and 50 nontumor patients, ATAD2 mRNA expression was upregulated in the HCC samples compared to the nontumor samples (10.75 ± 0.05668 vs. 9.338 ± 0.06266; *P* \< 0.0001, [Figure 2](#fig2){ref-type="fig"}). The overexpression of ATAD2 was correlated with race (*P* = 0.008), a family history of cancer (*P* = 0.018), and tumor grade (*P* \< 0.001) ([Table 3](#tab3){ref-type="table"}). Patients with G3-G4 had higher levels of ATAD2 expression than patients with G1-G2 (11.88 ± 0.07667 vs. 11.67 ± 0.06207; *P* = 0.033, [Figure 1(g)](#fig1){ref-type="fig"}). However, we did not observed any differential expression of ATAD2 mRNA among different races or family cancer histories (Figures [1(e)](#fig1){ref-type="fig"} and [1(f)](#fig1){ref-type="fig"}). In addition, no associations between sex, age, cirrhosis, histological type, tumor status, vascular tumor cell type, TNM stage, or T/N/M stage were observed (*P* \> 0.05, Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

3.2. ATAD2 Expression Is Associated with the Prognosis of HCC {#sec3.2}
-------------------------------------------------------------

Furthermore, the prognostic value of aberrant ATAD2 expression was examined in the CMUD and TCGA datasets. Univariate analysis indicated that ATAD2 expression status, tumor size, metastasis, serum AFP, and TNM stage unfavorably influenced OS (Table [S1](#supplementary-material-1){ref-type="supplementary-material"}). OS and disease-free survival (DFS) were significantly lower in patients with ATAD2 overexpression than in those with low ATAD2 expression (*P* \< 0.001, Figures [1(h)](#fig1){ref-type="fig"} and [1(i)](#fig1){ref-type="fig"}). In the tumor size and metastasis subgroup, patients with high ATAD2 levels had a poorer prognosis than those with low ATAD2 levels, regardless of tumor size or metastasis status (Figures [S4A](#supplementary-material-1){ref-type="supplementary-material"}--[S4D](#supplementary-material-1){ref-type="supplementary-material"}). Other subgroup analyses among patients with a serum AFP concentration \< 200 ng/ml or stage I + II revealed that the ATAD2-high group had a more unfavorable OS than the ATAD2-low group (both *P* \< 0.0001) (Figure [S4](#supplementary-material-1){ref-type="supplementary-material"}). The multivariate analysis showed that the ATAD2 expression status, serum AFP concentration, and metastasis were significant prognostic factors for HCC patients (Table [S1](#supplementary-material-1){ref-type="supplementary-material"}). Unfortunately, the OS curve from the ATAD2 mRNA high expression group was not different from that of the low expression group in the TCGA dataset (HR = 0.774, 95% CI: 0.531--1.127; *P* = 0.168, [Figure 1(j)](#fig1){ref-type="fig"}). However, the subgroup analysis among patients of the Asian race revealed that the ATAD2-high group was associated with an unfavorable OS (*P* = 0.020) (Figure [S4](#supplementary-material-1){ref-type="supplementary-material"}).

3.3. ATAD2 mRNA Expression in the GEO and Oncomine Databases {#sec3.3}
------------------------------------------------------------

To detect ATAD2 mRNA expression in other HCC-related databases, 27 databases, including GEO and Oncomine, were searched, yielding a total of 1,569 HCC samples and 1,356 nontumor samples. All the ATAD2 mRNA expression values are provided in [Table 3](#tab3){ref-type="table"}. The results suggested that ATAD2 mRNA expression was significantly increased in 1,417 HCC samples compared to that in 1,244 nontumor samples, except in the GSE14811, GSE46444, and GSE59259 datasets. No differences in ATAD2 expression between the HCC and nontumor groups in the GSE59259 dataset were observed (*P* = 0.593). Notably, the nontumor samples had higher levels of ATAD2 expression than the HCC samples in the GSE14811 and GSE46444 datasets (*P* = 0.002, *P* = 0.007). Scatter plots were drawn to visually represent the results ([Figure 2](#fig2){ref-type="fig"}). To explain the pooled analysis based on all data referring to ATAD2 expression in this article, a meta-analysis was conducted to comprehensively integrate the ATAD2 expression results from different databases. The pooled SMD reached 8.88 (95% CI: 5.96--11.81; *P* \< 0.001) using the random effects model ([Figure 3(a)](#fig3){ref-type="fig"}), indicating that ATAD2 is significantly overexpressed in HCC, which was based on its high percentage of amplification (68/110, 61.8%) and mRNA upregulation (31/110, 28.2%) in genetic alterations from cBioPortal (Figure [S2B](#supplementary-material-1){ref-type="supplementary-material"}).

3.4. Analysis of the Diagnostic Value of High ATAD2 Expression Based on TCGA, GEO, and Oncomine Databases {#sec3.4}
---------------------------------------------------------------------------------------------------------

The diagnostic value of ATAD2 expression in HCC was assessed based on the AUC of the ROC curve. In the TCGA dataset, the AUC of the ROC was 0.8839, with a cut-off value of 10.15 and a sensitivity and specificity of ATAD2 in diagnosing HCC of 70.32% and 98%, respectively ([Figure 3](#fig3){ref-type="fig"}). Glypican-3 (GPC3) is an important member of the glypican family and has been previously used as a marker for the early diagnosis of HCC \[[@B15]\]. As such, we compared its diagnostic performance among ATAD2, GPC3, and AFP (a traditional biomarker for HCC diagnosis) in 165 Asian cases (159 tumors and 6 nontumors) on the TCGA database. The results suggested that the specificity of ATAD2, GPC3, and AFP was 100%. The sensitivity of ATAD2 and GPC3 was 83.02% and 84.91%, respectively, which were both higher than that of AFP. The difference was statistically significant. Similar results were also observed when comparing the coincidence rate and area under the ROC curve. However, there was no significant difference between ATAD2 and GPC3 in terms of sensitivity, coincidence rate, and area under the ROC curve (Table [S2](#supplementary-material-1){ref-type="supplementary-material"}). In addition, the ROC curve plots of the GEO and Oncomine datasets were also drawn to visually represent the results ([Figure 4](#fig4){ref-type="fig"}). These results showed that ATAD2 overexpression had significant diagnostic value in HCC. Furthermore, the diagnostic accuracy was further evaluated by plotting the SROC and calculating the AUC, which was 0.89 (95% CI: 0.86--0.91). The pooled sensitivity, specificity, and DOR were 0.73 (95% CI: 0.68--0.77), 0.90 (95% CI: 0.87--0.93), and 8.88 (95% CI: 5.96--11.81), respectively. These results indicated that ATAD2 had a better discriminatory test performance and high diagnostic accuracy in distinguishing patients with HCC from healthy controls, similar to GPC3 (Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"}).

3.5. Identification of Aberrant ATAD2 Expression Related to Pathways by Bioinformatic Algorithms {#sec3.5}
------------------------------------------------------------------------------------------------

To gain further insights into the biological functions associated with ATAD2 upregulation, WGCNA algorithms were used. As a gene screening method, WGCNA analysis can be used to simplify complex microarray data into several functional modules correlated with clinical traits, which are composed of coexpressed genes. Subsequently, hub genes in the most prominent modules related to clinical traits were filtered and analyzed. Firstly, the DEGs were screened by defining *P* \< 0.05 and ∣logFC∣ ≥ 1 as the thresholds for 374 HCC samples in the TCGA database. In total, 9,219 DEGs were used to construct a coexpression network with the WGCNA package to identify a module of genes related to aberrant ATAD2 expression, which was calculated as a clinicopathological feature to be analyzed ([Figure 5(a)](#fig5){ref-type="fig"}). The module of genes shown in yellow, which includes 438 genes, was significantly related to ATAD2 expression ([Figure 5(d)](#fig5){ref-type="fig"}). To further investigate the functional associations of ATAD2-related genes, all 438 DEGs in the yellow module were submitted to the online database DAVID to identify representative GO terms and KEGG pathways \[[@B16]\] to elucidate the functional properties of the ATAD2-related DEGs. The top 10 GO and KEGG pathways sorted by the false discovery rate (FDR) are shown in Figures [5(b)](#fig5){ref-type="fig"} and [5(c)](#fig5){ref-type="fig"}. The results showed that the yellow module of genes contained biological processes mainly enriched in cell division, mitotic nuclear division, DNA replication, and DNA repair. The cellular components were enriched mainly in the nucleus, nucleoplasm, and centrosome. The molecular functions were enriched mainly in protein binding, ATP binding, DNA binding, and chromatin binding ([Figure 5(b)](#fig5){ref-type="fig"}). These results suggest that ATAD2 acts as a "nuclear factor" to maintain the physiological function of chromatin and DNA. Likewise, KEGG pathway analysis also showed that ATAD2-related DEGs were enriched in the cell cycle, DNA replication, oocyte meiosis, Fanconi anemia pathway, homologous recombination, mismatch repair, pyrimidine metabolism, the p53 signalling pathway, and base excision repair, which are significantly related to the synthesis, assembly, and repair of genetic material ([Figure 5(c)](#fig5){ref-type="fig"}). Remarkably, the KIFC1, SGO1, GINS1, and TPX2 genes were mostly related to aberrant ATAD2 expression in the yellow module of genes, whose correlation analysis *R* values were all greater than 0.9 ([Figure 5(e)](#fig5){ref-type="fig"}). Furthermore, according to the GS, MM, and MCODE results, we sorted the ATAD2-related DEGs (yellow module) and selected 30 members of each group to derive the intersection ([Figure 5(f)](#fig5){ref-type="fig"}). Finally, TTK was identified as the hub gene. Notably, the protein-protein interaction (PPI) network indicated that ATAD2 may interact with TTK ([Figure 5(g)](#fig5){ref-type="fig"}).

3.6. Downregulation of ATAD2 Resulted in G1 Phase Arrest in HCC Cell Lines {#sec3.6}
--------------------------------------------------------------------------

Based on the KEGG pathway analysis results, cell cycle tests were performed to further evaluate the effect of ATAD2 expression on cell cycle distribution. As shown in Figures [6(a)](#fig6){ref-type="fig"} and [6(b)](#fig6){ref-type="fig"}, the percentage of cells in G1 phase increased, while the percentage of cells in S phase decreased in HepG2 and Bel-7402 cells when ATAD2 expression was downregulated. We also examined cyclin C and cyclin D1; both of which are required for the G1/S transition of the cell cycle at the protein level. Western blotting indicated that the expression of cyclin C and cyclin D1 was decreased after the knockdown of the ATAD2 gene in HepG2 and Bel-7402 cells (Figures [6(c)](#fig6){ref-type="fig"} and [6(d)](#fig6){ref-type="fig"}). These findings indicated that aberrant ATAD2 expression was correlated with the cell cycle process from the KEGG analysis, which was also consistent with the results from our previous study.

4. Discussion {#sec4}
=============

HCC is the second leading cause of cancer-related death in East Asia, with over 50% of new cases being diagnosed in China. Chronic viral hepatitis and alcohol consumption are recognized as the two most important risk factors for the development of liver cirrhosis and, subsequently, HCC on a global scale. The development of HCC is complex and involves sustained inflammatory damage leading to hepatocyte necrosis, regeneration, and fibrotic deposition \[[@B17]\]. A failure to distinguish between groups at risk and the healthy population has been a leading factor in the delay of HCC diagnosis. Once diagnosed in the advanced stages, there are fewer curative treatment options available for patients. In addition to identifying HCC-related risk factors, the screening of potential candidates for clinical diagnosis and targeted therapy is necessary. As a conserved AAA ATPase and BRD factor, ATAD2 has received attention because of its vital functions in chromatin modification, protein complex assembly, and the promotion of gene transcription activation \[[@B5], [@B11], [@B18]--[@B21]\]. Despite these vital functions, ATAD2 has not been identified as a critical component in many molecular mechanism studies undertaken in recent years. Moreover, low levels of ATAD2 expression were reported after a comparison of metastatic and nonmetastatic breast cancer patients and controls, which differed from plausibly consistent viewpoints that ATAD2 was highly expressed in many cancers \[[@B22]\]. We also found that ATAD2 expression in different HCC datasets from the GEO did not remain stable. Hence, based on a large-scale sample size, which included data from our institution and from open-access online datasets, the expression of ATAD2 may be a reliable and valuable indicator. In addition, the positive research progress on small molecule inhibitors acting on BRDs has made it possible to target these BRD-containing proteins, such as ATAD2, for the diagnosis and treatment of HCC \[[@B23], [@B24]\].

In this study, we first systematically examined the expression of ATAD2 in HCC based on a large sample population, integrating data from our institution and from the GEO, Oncomine, and TCGA datasets. A pooled analysis showed that ATAD2 was significantly overexpressed in almost all HCC-related datasets. High ATAD2 expression was positively related to tumor size, metastasis, serum AFP concentration, and TNM stage in our study. The TCGA dataset results indicated that a high level of ATAD2 expression was closely correlated with race, a family cancer history, tumor grade, and disease stage. Both datasets highlighted the associations between aberrant ATAD2 expression and poor clinicopathological characteristics. Similar results have also been found in other ATAD2-related studies, such as those on colorectal cancer \[[@B25]\], gastric cancer \[[@B9]\], and cervical cancer \[[@B26]\], in which overexpressed ATAD2 levels often existed in more aggressive tumor subgroups. Likewise, the analysis of the TCGA dataset indicated that patients with G3-G4 had higher ATAD2 levels than those with G1-G2, supporting these findings. Furthermore, high levels of ATAD2 expression in HCC are a strong and independent predictor of shortened OS and DFS, although this result was not achieved when analyzing the TCGA dataset. These contradictory results could be explained by the subgroup analysis of ATAD2 expression on race from the TCGA dataset. However, we found that aberrant ATAD2 expression was closely related to different populations in the TCGA dataset, and a high level of ATAD2 expression among patients of the Asian race unfavorably influenced OS compared to a low level of ATAD2 expression. The results above were similar to those obtained from our institutional ISH sample, which consisted of Asian individuals. Subgroup analyses were also conducted. Tumor size and metastatic status seemed to have little effect on the prognostic value of ATAD2 expression status on OS. However, among patients with a serum AFP concentration \<200 ng/ml or stage I + II, the ATAD2-high group had a worse prognosis than the ATAD2-low group (both *P* \< 0.0001). These results correlate with those previously reported by Hwang \[[@B27]\].

In view of the aggressive biological features of ATAD2 emerging in tumors, particularly in HCC, we explored the possible clinical usage of ATAD2 for the detection and diagnosis of HCC. By combining the data on tissue ATAD2 levels from open datasets, including TCGA, GEO, and Oncomine, which included 1,569 HCC samples and 1,356 controls, we found that ATAD2 had a moderate diagnostic accuracy for HCC. As shown in [Figure 5](#fig5){ref-type="fig"}, the AUCs of the ROC curves in 23 of 28 datasets were greater than 0.75. A significant diagnostic value of ATAD2 expression in the tissues of patients with HCC compared to the healthy controls was observed. In addition, this diagnostic value of ATAD2 for HCC was also observed in comparison with GPC3 and AFP. Compared with AFP, a traditional detection marker, both ATAD2 and GPC3, has shown advantages over AFP in the diagnosis of HCC, even though this advantage seems to be more apparent in GPC3. However, when hepatitis occurs, the expression level of GPC3 in liver cells also increased \[[@B28]\]. To some extent, this increased the false positive rate of HCC diagnosis, resulting in a biased diagnosis. As a novel biomarker, the expression of ATAD2 in HCC was not associated with hepatitis cirrhosis in our own data, which indicated the advantages of ATAD2 over GPC3 for the diagnosis of HCC. More importantly, the SROC results also showed that ATAD2 yielded an AUC of 0.89, indicating that the efficiency of ATAD2 for HCC diagnosis was considerable, with upper-moderate sensitivity and specificity. As in AFP and GPC3 detection, ATAD2 may become a prospective molecular biomarker, allowing for the early diagnosis and treatment of HCC patients, thereby avoiding the adverse effects of tumor progression.

Normally, ATAD2 gene expression is tightly regulated by mitogenic signalling in proliferating cells, a process that is prominently observed in male germ cells and embryonic stem (ES) cells \[[@B12], [@B29]\]. Dysregulated control may cause ATAD2 upregulation, which can ultimately lead to carcinogenesis \[[@B12], [@B30]\]. A loss of inhibition upstream or by specific genetic modifications plays a vital role in aberrant ATAD2 expression. For instance, our previous study demonstrated that as an antioncogene, miR-372 was an upstream target of ATAD2, which was bound directly to its 3′ untranslated region (3′ UTR). In HCC, low miR-372 expression caused by the methylation of CpG in the promoter region ultimately led to the upregulation of ATAD2 expression \[[@B13], [@B31]\]. In addition to the posttranscriptional level of regulation, PPIs also play a part in ATAD2 expression. Both E2F1 and AR may enhance ATAD2 expression by acting at the ATAD2 promoter \[[@B11], [@B32]\]. Moreover, ATAD2 also acts as a direct target of certain protooncogenes, such as ACTR, AIB1, and SRC-3, integrating and/or activating multiple oncogenic programs or pathways to enhance tumorigenesis \[[@B7], [@B19], [@B33]\]. Of course, the amplification of the ATAD2 gene locus is also essential \[[@B34]\], as our cBioPortal analysis revealed that ATAD2 had a high percentage of amplification (68/110, 61.8%) among the genetic alterations. Regardless of the pathways that cause dysregulation, ATAD2 overexpression indeed damaged the maintenance of the ATAD2-related physiological process. Previous studies have suggested that ATAD2 functions as a transcriptional regulator and participates in the management of gene expression. As a coactivator of hormone receptors (ER*α* and AR) and c-myc, ATAD2 directly mediates the transcription of hormone receptor-related and c-myc pathway target genes \[[@B1], [@B3], [@B12]\]. The results of the GO analysis of ATAD2 molecular functions indicate the structural basis of the transcriptional function of ATAD2.

In addition to managing transcription, ATAD2 also appears to be involved in very specific and unique cellular processes, such as DNA repair and chromatin remodelling. By using a bioinformatics-based analysis, we observed that ATAD2 overexpression was closely related to cell division, mitotic nuclear division, DNA replication, and DNA repair. According to the ISH results of the nuclear-expressed protein, the cellular components identified by the GO analysis were enriched mainly in the nucleus, nucleoplasm, and centrosome. Cell cycle tests in the HepG2 and Bel-7402 HCC cells also demonstrated that ATAD2 and its related DEGs participate in cell cycle processes. These results were also consistent with Ciro\'s and Mjelle\'s findings, in which ATAD2 was consistently highly expressed in G1/S phase \[[@B5], [@B35]\]. Importantly, cyclin C and cyclin D1 protein expression was significantly inhibited when ATAD2 was not expressed. This evidence indicates that ATAD2 plays a vital role in regulating the cell cycle. In addition, based on the unique structure of ATAD2 itself, we also believe that ATAD2 acts as a generalist facilitator via protein recruitment at acetylated chromatin regions or via multimerization by its ATPase functions. Furthermore, the analysis of the KIFC1, SGO1, GINS1, and TPX2 genes revealed that these genes are mostly related to aberrant ATAD2 expression, which may explain the interactions between them, although further experiments are needed. By integrating multiple datasets, TTK, a dual-specificity protein kinase, was identified and may interact with ATAD2 based on the PPI network analysis. TTK is a component of the spindle assembly checkpoint, a surveillance mechanism that ensures the fidelity of chromosome segregation \[[@B36]\]. Previous studies have shown that TTK is often overexpressed in many cancers and that the upregulation of TTK is correlated with poor survival \[[@B37], [@B38]\]. The inhibition of TTK kinase activity has been previously found to lead to chromosome segregation errors, resulting in cancer \[[@B39], [@B40]\]. King et al. \[[@B41]\] found that high TTK expression levels accelerated the TGF-*β* signalling pathways to induce the epithelial-to-mesenchymal transition (EMT) in triple-negative breast cancer. The relationships between ATAD2 and TTK should be further tested. Thus, it was observed that ATAD2 is involved in controlling the key components of DNA repair, cell proliferation, and metastasis pathways, eventually resulting in more aggressive tumors. However, with the continuous progress of drug research, some small molecule inhibitors of ATAD2\'s BRD have been identified as novel drugs.

Although quite dissimilar to other druggable BRDs, ATAD2 has been considered "difficult to drug" because of its unique BRD structure \[[@B42]\]. Thus, it appears that more work is needed before the ATAD2 protein can become a promising target for the treatment of cancers in the future.

5. Conclusions {#sec5}
==============

In the present study, we used integrated bioinformatics datasets with data from our institution to find that ATAD2 was overexpressed in HCC. High ATAD2 expression levels were positively related to aggressive phenotypes and poor survival in HCC. ATAD2 showed significant diagnostic value in patients with HCC. Functional GO and KEGG analyses suggested that ATAD2 overexpression participates in cell cycle regulation. ATAD2 might interact with TTK to accelerate HCC carcinogenesis.
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![IHC staining of ATAD2 in HCC tissues and expression and prognosis of ATAD2 in HCC based on TCGA and our institutional data. Positive immunohistochemical reaction was showed as brown staining. Representative tissue sections with different immunochemical staining status (from nucleus to negative) of ATAD2: (a) nucleus: poorly differentiated; (b) cytoplasm: moderately poorly differentiated; (c) less cytoplasm: moderately differentiated; (d) negative: well differentiated. For each intensity group, the specimens were obtained (×200 and ×400 magnification). (e) Scatter plot of ATAD2 expression at different races. (f) Scatter plot of ATAD2 expression based on family cancer history. (g) Scatter plot of ATAD2 expression at different histological grades. (h) Overall survival of HCC patients related to ATAD2 status (protein level) in institutional data. (i) Disease-free survival of HCC patients related to ATAD2 status (protein level) in institutional data. (j) Overall survival of HCC patients related to ATAD2 status (mRNA level) based on TCGA data.](BMRI2020-8657468.001){#fig1}

![Levels of ATAD2 expression in HCC vs. nontumor tissues based on 28 datasets.](BMRI2020-8657468.002){#fig2}

![A meta-analysis of ATAD2 differential expression in HCC vs. nontumor tissues based on 28 datasets. (a) Forest plot on ATAD2 expression between HCC and nontumor tissues. (b) SROC curves for ATAD2 differential expression in HCC patients from nontumor tissues.](BMRI2020-8657468.003){#fig3}

![ROC curves of ATAD2 expression in HCC vs. nontumor tissues based on 28 datasets.](BMRI2020-8657468.004){#fig4}

![Identification of ATAD2-related genes and GO and KEGG pathway analysis of the ATAD2-related genes in HCC. (a) Volcano plot of the differential expression genes in HCC vs. normal liver tissues based on TCGA. Red indicates high expression and green indicates low expression (∣log2FC∣ \> 1 and adjusted *P* value \<0.05). (b, c) The *x*-axis showed the number of genes and the *y*-axis showed the GO and KEGG terms; (d) Heat map of the correlation between module eigengenes and clinical traits including ATAD2 aberrant expressions of HCC by using the WGCNA package of R language: each row indicated a module eigengene, and each column indicated a clinicopathological parameter. Each block contained the corresponding correlation coefficient and *P* value. (e) Scatter plot of module eigengenes related to ATAD2 aberrant expression in the yellow set. (f) Hub genes were filtered out with module membership (MM), gene significance (GS), and MCODE degree. (g) Protein-protein interaction network of ATAD2, TTK, KIFC1, SGO1, GINS1, and TPX2 in the yellow set.](BMRI2020-8657468.005){#fig5}

![(a, b) RNAi lentivirus-mediated ATAD2 knockdown reduced HepG2 and Bel-7402 cell proliferation and led to a G1 phase cell cycle arrest. (c, d) cyclin C and cyclin D1 expressions in protein levels were detected when ATAD2 gene was downregulated by siRNA in HepG2 and Bel-7402 cell lines.](BMRI2020-8657468.006){#fig6}

###### 

Characteristics of datasets included in this study.

  First author (publication year)   Country/region   Dataset                   Platform              Samples                                       Cancer   Nontumor                          
  --------------------------------- ---------------- ------------------------- --------------------- --------------------------------------------- -------- ---------- ------- ----- -------- -------
  Kim B et al. (2009)               South Korea      GEO:GSE14811              KRIBB GLP8177         Pair-matched HCC vs. adjacent liver tissues   56       -0.040     0.033   56    0.111    0.034
  Ozturk M et al. (2009)            Turkey           GEO:GSE17548              Affymetrix GPL570     Cirrhosis liver vs HCC                        17       7.967      0.267   20    6.968    0.148
  Archer KJ et al. (2009)           USA              GEO:GSE17967              Affymetrix GPL571     Cirrhosis liver with or without HCC           16       6.477      0.179   47    5.768    0.094
  Bonacci B et al. (2010)           USA              GEO:GSE22045              Affymetrix GPL570     Pair-matched HCC vs. adjacent liver tissues   24       6.034      0.191   24    5.047    0.051
  Zhang C et al. (2010)             USA              GEO:GSE25097              Affymetrix GPL10687   Cirrhotic and normal livers vs HCC            268      2.818      0.109   289   0.788    0.024
  Huang Y et al. (2011)             Taiwan           GEO:GSE33006              Affymetrix GPL570     Pair-matched HCC vs. adjacent liver tissues   3        10.150     0.209   3     8.246    0.160
  Lim HY et al. (2012)              South Korea      GEO:GSE36376              Illumina GPL10558     Pair-matched HCC vs. adjacent liver tissues   240      7.576      0.040   193   6.806    0.016
  Kim J et al. (2012)               USA              GEO:GSE39791              Illumina GPL10558     Pair-matched HCC vs. adjacent liver tissues   72       7.636      0.055   72    7.106    0.028
  Darpolor MM et al. (2013)         USA              GEO:GSE45050              Affymetrix GPL6244    Cirrhotic and normal livers vs HCC            6        8.532      0.406   10    7.683    0.141
  Wei L et al. (2013)               China            GEO:GSE45114              CapitalBio GPL5918    Normal vs. HCC and pericancer tissues         24       1.341      0.226   25    -0.086   0.171
  Jeng Y et al. (2013)              Taiwan           GEO:GSE46408              Agilent GPL4133       Pair-matched HCC vs. adjacent liver tissues   6        10.210     0.386   6     7.636    0.221
  Chen X et al. (2013)              USA              GEO:GSE46444              Illumina GPL13369     Liver tissues vs. HCC from HCC patients       88       7.478      0.106   48    7.961    0.139
  Geffers R et al. (2013)           Germany          GEO:GSE50579              Agilent GPL14550      Liver cell and normal liver vs. HCC           70       10.500     0.126   10    9.037    0.118
  Villa E et al. (2014)             Italy            GEO:GSE54236              Agilent GPL6480       Pair-matched HCC vs. adjacent liver tissues   81       7.534      0.119   80    6.689    0.077
  Melis M et al. (2014)             USA              GEO:GSE55092              Affymetrix GPL570     Cirrhosis liver vs HCC                        49       7.016      0.119   91    6.132    0.034
  Hoshida Y et al. (2014)           USA              GEO:GSE56140              Illumina GPL18461     Cirrhosis liver vs HCC                        35       8.806      0.106   34    7.991    0.044
  Mah W et al. (2014)               Singapore        GEO:GSE57957              Illumina GPL10558     Pair-matched HCC vs. adjacent liver tissues   39       9.173      0.123   39    8.410    0.067
  Udali S et al. (2014)             Italy            GEO:GSE59259              NimbleGen GPL18451    Alcohol-cirrhosis liver vs HCC                8        10.490     0.310   8     10.710   0.145
  Kao KJ et al. (2014)              Taiwan           GEO:GSE60502              Affymetrix GPL96      Pair-matched HCC vs. adjacent liver tissues   18       9.241      0.209   18    7.808    0.101
  Zucman-Rossi J et al. (2014)      France           GEO:GSE62232              Affymetrix GPL570     Normal vs. HCC                                81       7.569      0.131   10    6.013    0.130
  Makowska Z et al. (2014)          Switzerland      GEO:GSE64041              Affymetrix GPL6244    Normal vs. HCC                                60       7.589      0.111   65    6.796    0.043
  Tao Y et al. (2015)               China            GEO:GSE74656              Affymetrix GPL16043   Pair-matched HCC vs. adjacent liver tissues   10       6.990      0.278   5     5.727    0.173
  Grinchuk OV et al. (2015)         Singapore        GEO:GSE76427              Illumina GPL10558     Pair-matched HCC vs. adjacent liver tissues   115      8.656      0.064   52    8.009    0.065
  Qin W et al. (2016)               China            GEO:GSE84402              Affymetrix GPL570     Pair-matched HCC vs. adjacent liver tissues   14       6.801      0.312   14    5.086    0.247
  Hui KM et al. (2018)              Singapore        GEO:GSE121248             Affymetrix GPL570     Cirrhosis liver vs HCC                        70       8.041      0.111   37    6.893    0.126
  Wurmbach E et al. (2007)          USA              Oncomine:Wurmbach liver   Affymetrix GPL570     Cirrhosis liver vs. HCC and relapse tissues   35       8.049      0.234   40    6.263    0.088
  Mas VR et al. (2009)              USA              Oncomine:Mas liver        Affymetrix GPL96      Cirrhosis liver vs. HCC and relapse tissues   64       6.463      0.109   60    6.080    0.084

Abbreviation: SD: standard deviation.

###### 

Distribution of ATAD2 and clinicopathological characteristics from institutional HCC patients.

  Characteristics   No. of patients   ATAD2   *χ* ^2^   *P*     
  ----------------- ----------------- ------- --------- ------- -------
  Tissue                                                        
   Tumor            80                28      52        8.046   0.006
   Normal tumor     20                14      6                 
  Gender                                                        
   Male             66                25      41        1.374   0.357
   Female           14                3       11                
  Age (year)                                                    
   \<50             25                7       18        0.783   0.454
   ≥50              55                21      34                
  Tumor size                                                    
   ≥5 cm            35                7       28        6.154   0.018
   \<5 cm           45                21      24                
  Metastasis                                                    
   Yes              30                5       25        7.092   0.009
   No               50                23      27                
  Invasion                                                      
   Yes              27                6       21        2.925   0.136
   No               53                22      31                
  Cirrhosis                                                     
   Yes              76                27      49        0.185   1.000
   No               4                 1       3                 
  HBsAg                                                         
   Positive         64                22      42        0.055   1.000
   Negative         16                6       10                
  AFP                                                           
   \<200 ng/dl      57                25      32        6.841   0.010
   ≥200 ng/dl       23                3       20                
  TNM stage                                                     
   I + II           50                22      28        4.747   0.033
   III + IV         30                6       24                
  Differentiation                                               
   WD               35                16      19        3.391   0.184
   MD               35                10      25                
   PD               10                2       8                 

Abbreviations: WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated.

###### 

Distribution of ATAD2 and clinicopathological characteristics from TCGA LIHC patients.

  Characteristics            No. of patients   ATAD2   *χ* ^2^   *P*      
  -------------------------- ----------------- ------- --------- -------- ---------
  Tissue                                                                  
   Tumor                     374               216     158       33.670   \<0.001
   Nontumor                  50                50      0                  
  Gender                                                                  
   Male                      234               129     105       0.478    0.560
   Female                    110               65      45                 
  Age                                                                     
   \<50                      70                32      38        4.077    0.058
   ≥50                       274               162     112                
  Race                                                                    
   Asian                     155               72      83        11.843   0.008
   American Indian           2                 1       1                  
   White                     164               107     57                 
   Black                     14                9       5                  
  Cirrhosis                                                               
   Negative                  179               105     74        0.896    0.370
   Positive                  146               78      68                 
  Histological type                                                       
   HCC                       334               185     149       4.904    0.086
   ICC                       7                 6       1                  
   FL-HCC                    3                 3       0                  
  Family cancer history                                                   
   No                        199               105     94        6.025    0.018
   Yes                       99                67      32                 
  Grade                                                                   
   G1-G2                     214               144     70        27.331   \<0.001
   G3-G4                     130               50      80                 
  Tumor status                                                            
   Tumor free                222               124     98        0.004    1.000
   With tumor                96                54      42                 
  Vascular tumor cell type                                                
   None                      194               118     76        2.650    0.109
   Micro/macro               102               52      50                 
  Stage                                                                   
   I-II                      254               144     110       0.035    0.902
   III-IV                    90                50      40                 
  T stage                                                                 
   T1-T2                     258               147     111       0.142    0.709
   T3-T4                     86                47      39                 
  N stage                                                                 
   N0                        340               191     149       0.570    0.635
   N1-N3                     4                 3       1                  
  M stage                                                                 
   M0                        339               190     149       1.150    0.392
   M1                        5                 4       1                  

Abbreviations: HCC: hepatocellular carcinoma; ICC: hepatocholangiocarcinoma; FL-HCC: fibrolamellar carcinoma.
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